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converting enzyme inhibitors to 
larvae of the disease vectors Aedes 
aegypti and Anopheles gambiae
Zatul-’Iffah Abu Hasan1,2, Helen Williams3, Nur M. Ismail4, Hidayatulfathi Othman4, 
Gyles E. Cozier5, K. Ravi Acharya5 & R. Elwyn Isaac2
The control of mosquitoes is threatened by the appearance of insecticide resistance and therefore new 
control chemicals are urgently required. Here we show that inhibitors of mosquito peptidyl dipeptidase, 
a peptidase related to mammalian angiotensin-converting enzyme (ACE), are insecticidal to larvae 
of the mosquitoes, Aedes aegypti and Anopheles gambiae. ACE inhibitors (captopril, fosinopril and 
fosinoprilat) and two peptides (trypsin-modulating oostatic factor/TMOF and a bradykinin-potentiating 
peptide, BPP-12b) were all inhibitors of the larval ACE activity of both mosquitoes. Two inhibitors, 
captopril and fosinopril (a pro-drug ester of fosinoprilat), were tested for larvicidal activity. Within 
24 h captopril had killed >90% of the early instars of both species with 3rd instars showing greater 
resistance. Mortality was also high within 24 h of exposure of 1st, 2nd and 3rd instars of An. gambiae to 
fosinopril. Fosinopril was also toxic to Ae. aegypti larvae, although the 1st instars appeared to be less 
susceptible to this pro-drug even after 72 h exposure. Homology models of the larval An. gambiae ACE 
proteins (AnoACE2 and AnoACE3) reveal structural differences compared to human ACE, suggesting 
that structure-based drug design offers a fruitful approach to the development of selective inhibitors of 
mosquito ACE enzymes as novel larvicides.
The mosquitoes Anopheles gambiae and Aedes aegypti are some of the most deadly insects because of their effec-
tiveness as vectors of malaria and a range of arboviruses, including yellow fever, dengue, chikungunya and zika. 
The close association of Ae. aegypti with urbanisation in tropical and sub-tropical countries and the ease of 
trans-global human travel and the mass migrations from war zones presents particular challenges in disrupting 
the cycle of arbovirus infections transmitted by Ae. aegypti in human populations1,2. The lack of effective vaccines 
and treatments for dengue, chikungunya and zika has focused attention on integrated vector control management 
based on environmental/cultural management, chemical and biological control2. The use of insecticides from dif-
ferent chemical classes is a key component of the integrated strategy against both An. gambiae and Ae. aegypti, but 
the ever increasing problem of insecticide resistance means that new compounds with different modes of action 
are urgently needed to replace chemicals that fail to control resistant mosquito populations3–6.
In our search for new insecticide targets that interfere with peptide hormone metabolism, we have previously 
identified a peptide-degrading zinc-metallopeptidase, known as angiotensin converting enzyme (ACE) from the 
role of the mammalian enzyme in the renin-angiotensin systems7–9, as a potential target for the development 
of inhibitors that disrupt insect reproduction. The dual role of the enzyme in the processing of the mammalian 
vasoconstrictor angiotensin II and the inactivation of the vasodilatory bradykinin led to the development of 
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inhibitors of human ACE as anti-hypertensive drugs10–12. The first inhibitors were in fact natural proline-rich 
peptides (BPPs) with bradykinin-potentiating activity isolated from the venom of the snake Bothrops jararaca, 
but these lacked oral activity13–15.
Insect ACE, like the mammalian enzyme, is a promiscuous peptidase that cleaves dipeptides from the car-
boxyl end of oligopeptides and, in some instances, can cleave amidated di- or tri-peptides from substrates with 
an amidated carboxyl terminus, a common feature of insect neuropeptides16–21. Insect ACEs are generally sol-
uble enzymes secreted from cells into the extracellular milieu, where like their mammalian counterparts they 
degrade peptides by sequential removal of dipeptides16,22–24. Much of our knowledge of the biochemistry and 
structural biology of insect ACE comes from studying the Drosophila melanogaster enzyme known as AnCE21,25. 
This peptidyl dipeptidase is strongly expressed as a glycosylated protein of 72 kDa in several tissues, including 
male reproductive tissues, the larval and adult midgut, larval trachea and adult salivary gland26,27. Other insect 
species also express ACE in reproductive tissues of both sexes, suggesting a broader physiological role for the 
enzyme in insect reproduction19,28–36. Insect ACE not only resembles the mammalian enzyme in its substrate 
specificity, but also in susceptibility to inhibitors such as captopril, lisinopril, fosinoprilat, enalapril and tran-
dolaprilat, but apart from captopril these inhibitors can be far less potent towards insect ACE compared to mam-
malian ACE22,23. Nevertheless, ACE inhibitors can be acutely toxic to insects, which contrasts with their life-span 
extending properties in rodents37 and the nematode, Caenorhabditis elegans38. They have been useful in confirm-
ing important roles for ACE in reproduction, growth and development in several insect species30,34,35,39. In the 
mosquito Anopheles stephensi, females fed with ACE inhibitors in the blood meal or females mated with males 
supplied with ACE inhibitors in their sugar diet, lay significantly fewer eggs than normal32,35,40.
ACE inhibitors can also interfere with insect larval development as was shown by the stunting of larval growth 
of the tobacco hornworm, Manduca sexta, by injection of captopril, lisinopril and fosinoprilat into 4th instar 
insects. Injection of the prodrug fosinopril into the same larval stages resulted in no weight gain and death within 
a few days. The injection of ACE inhibitors (captopril, lisinopril and enalapril) combined with the diuretic pep-
tides (helicokinin I, II and III) into 5th instar larvae of the tobacco budworm (Heliothis virescens) resulted in 
lethality, however, the inhibitors on their own were not toxic. In the present study we have asked the question 
whether mosquito larval stages, like the juvenile stages of some other insect species, are susceptible to ACE inhibi-
tors. We now show that several synthetic ACE inhibitors are powerful blockers of the peptidyl dipeptidase activity 
found in a soluble fraction from both Ae. aegypti and An. gambiae larvae. The snake venom peptide BPP-12b, and 
the proline-rich trypsin-modulating oostatic factor (TMOF), which is toxic to Ae. aegypti larvae41, also inhibited 
the larval peptidase activity. When captopril and fosinopril (Fig. 1), two inhibitors with different modes of inter-
action with the ACE active site, were added to the rearing water high levels of larval mortality of were observed 
confirming the potential of insect ACE inhibitors as mosquito larvicides.
Results and Discussion
Inhibition of the soluble peptidyl dipeptidase (insect ACE) activity from whole larvae of Ae. 
aegypti and An. gambiae. Members of the insect ACE family of peptidyl dipeptidases are generally soluble 
secreted proteins, whereas mammalian ACEs are mainly membrane tethered. In order to ascertain whether the 
ACE activity of the mosquito larvae was soluble or membrane-bound, homogenates were prepared from 3rd instar 
Ae. aegypti and An. gambiae and centrifuged at 55,000 g for 1 h to sediment cellular membranes. By measuring 
the peptidase activity before and after centrifugation, it was clear that the majority of the insect ACE remained 
in the high-speed supernatant and that most of the peptidase activity was inhibited by captopril (Fig. 2). The 
soluble enzyme from both mosquito species was then used to determine the relative potency of synthetic (cap-
topril, fosinopril and fosinoprilat) and natural peptide (BPP-12b and TMOF) ACE inhibitors. Apart from the 
pro-drug fosinopril, all the inhibitors showed a greater degree of potency towards the Ae. aegypti activity, with 
captopril being the most potent (Fig. 3). For the enzyme prepared from both species, fosinopril was weaker than 
the non-esterified fosinoprilat in inhibiting the activity. The snake venom peptide BPP-12b and the mosquito 
Figure 1. Chemical structures of inhibitors of mosquito larval peptidyl dipeptidase activity. 
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peptide TMOF both inhibited mosquito ACE activity, but were much less potent than the synthetic compounds 
with BPP-12b having IC50 values two orders of magnitude lower than those of TMOF. Interestingly, both natural 
peptides were stronger inhibitors of the Ae. aegypti ACE compared to An. gambiae (Table 1).
The toxicity of ACE inhibitors to larval instars of Ae. aegypti and An. gambiae. The juvenile part 
of the mosquito life-cycle involves four larval instars (L1, L2, L3 and L4) of rapid growth and three larval moults 
before the transition to a pupa and complete metamorphosis to the adult. We investigated the effect of captopril 
and fosinopril on the survival of three larval stages (L1, L2 and L3) of both Ae. aegypti and An. gambiae by adding 
the chemicals to the water environment with the larval food followed by assessing mortality after 24, 48 and 72 h. 
High mortality was recorded for three larval instars (L1, L2 and L3) of Ae. aegypti after the first 24 h of treatment 
with captopril and by 48 h essentially all L1 and L2 insects were dead (Fig. 4a). The L3 instars were slightly more 
resistant to captopril, nevertheless by 72 h mortality of these insects had reached around 90%. Very similar results 
were obtained when L1 and L2 larvae of An. gambiae were treated in an identical manner with captopril (Fig. 4b). 
The L3 insects were, however, more resistant compared to Ae. aegypti at the same stage of development. Even after 
72 h only 10% of the An. gambiae L3 larvae had succumbed to the inhibitor.
High levels of larval mortality were also recorded for Ae. aegypti treated with fosinopril (Fig. 4c). L1 larvae 
however appeared to be more resistant compared to the other two instars even after 72 h of treatment, which 
might reflect a lower metabolic conversion of the pro-drug to the active inhibitor fosinoprilat. On the other hand 
fosinopril showed high levels of toxicity to all three instars of An. gambiae with over 80% mortality within 24 h 
and over 95% mortality by 48 h of treatment (Fig. 4d).
We have shown previously that ACE inhibitors fed to adult mosquitoes can have profound effects on female 
fecundity, suggesting that the mosquito peptidyl dipeptidase is a potential target for the development of novel 
mosquito control chemicals32,35,40. We have now provided data supporting this view from a study of the effects of 
ACE inhibitors on the development and survival of larval instars of both Ae. aegypti and An. gambiae. Captopril 
was one of the first generation of orally active ACE inhibitors and is also the smallest, interacting with only two 
enzyme sub-sites (S1′ and S2′ ). These sub-sites have been labelled based around the peptide bond that is cleaved 
such that the pockets that bind the dipeptide that is released by the enzyme are labelled S1′ and S2′ sub-sites, and 
the dipeptide itself is labelled P1′ and P2′ . The rest of the peptide is labelled P1, P2, etc, which bind in subsites S1, 
S2, etc, with the peptide being cleaved between residues P1 and P1′ . Key to the design of captopril was the inclu-
sion of a sulfhydryl group that interacts with the active site zinc. Other ACE inhibitors can be of a larger design 
enabling interaction with more than two enzyme sub-sites and may have a different zinc-binding ligand. In the 
case of fosinoprilat, a hydroxyphosphinyl group interacts with the zinc and this larger molecule binds at three 
sub-sites (S1, S1′ and S2′ ) of the enzyme. It is possible that off-target interactions are responsible or contribute to 
the toxicity observed in this study, however the fact that two ACE inhibitors from different chemical classes show 
similar toxic effects suggests that mosquito ACE is indeed the likely primary target. The concentration of inhibi-
tor required for toxicity is much higher than the in vitro potency as inhibitors of the larval ACE, indicating some 
limited availability of the chemicals to the in vivo enzyme. We expect that the water soluble inhibitors are taken up 
orally with the food rather than through the cuticle. The mosquito larvae feed by filtering out organic particulate 
matter from the water, a mode of feeding that will limit ingestion of the inhibitors via the oral route. The pro-drug 
Figure 2. The relative activity of peptidyl dipeptidase (ACE) in a homogenate of mosquito larvae before 
and after high-speed centrifugation. Aliquots were removed for activity assay from the homogenate before and 
after centrifugation at 55,000 g for 1 h. The activity in the high-speed supernatant is expressed relative (%) to the 
activity of the homogenate prior to centrifugation. The results are expressed as the mean ± SEM. (n = 4).
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fosinopril has greater hydrophobicity to improve bioavailability and undergoes metabolic de-esterification to 
fosinoprilat, the active inhibitor. These chemical properties and the requirement that fosinopril undergoes meta-
bolic activation are likely to be important factors in determining the toxicity of the inhibitor to mosquito larvae.
We tested BPP-12b, a member of the BPP family of peptides originally isolated from the venom of the pit 
viper, Bothrops jararaca, as an inhibitor of mosquito peptidyl dipeptidase and showed that the proline-rich pep-
tide was a powerful natural inhibitor of the activity in both species. The presence of the Pro-Pro sequence at 
the C-terminus and a pyroglutamate at the N-terminus protects these peptides from metabolic degradation by 
exo-peptidases7,42. TMOF is a mosquito peptide isolated from the ovaries of adult Ae. aegypti that is also proline 
rich and therefore it was not surprising that it too inhibits mosquito larval peptidase activity, albeit with reduced 
potency relative to BPP-12b. TMOF is involved in regulating egg development and blood digestion following a 
blood meal43. It appears to work by inhibiting the biosynthesis of midgut trypsin and not by inhibition of the pro-
tease activity41. TMOF also inhibits trypsin biosynthesis in larval instars and has been used as a larvicide against 











































Figure 3. Inhibition of the peptidyl dipeptidase (ACE) activity of (a) Ae. aegypti and (b) An. gambiae larvae. 
Inhibition curves for captopril, fosinopril, fosinoprilat, PBB12b and TMOF were generated by assaying peptidyl 
dipeptidase activity of the high-speed supernatant prepared from a homogenate in the presence of different 
inhibitor concentrations using the assay described in the materials and methods section. Data is expressed 
relative to uninhibited activity.
Inhibitor
Aedes aegypti Anopheles gambiae






Table 1.  IC50 values for the inhibition of larval peptidyl dipeptidase (ACE) activity.
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Figure 4. Larvicidal activity of captopril and fosinopril against Ae. aegypti and An. gambiae larvae. Larvae 
of Ae. aegypti (a and c) and An. gambiae (b and d) were placed in water containing food with either 5 mM 
captopril (a and b) or 5 mM fosinopril (c and d). Mortality was assessed every 24 h. In the absence of inhibitor 
all larvae survived and successfully developed into pupae. Data are expressed as the mean ± SD (n = 6).
Figure 5. Cartoon representation overlay of human tACE- and AnCE-captopril complex crystal structures 
with modelled AnoACE2 and AnoACE3. tACE is shown in orange, AnCE in purple, AnoACE2 in blue and 
AnoACE3 in green. The captopril ligands are shown as spheres. The figure was generated using Pymol59.
www.nature.com/scientificreports/
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is not a particularly potent inhibitor of larval mosquito ACE, nevertheless this inhibition might contribute in a 
minor way to the toxicity against Ae. aegypti larvae.
The insect ACE gene family has expanded greatly in mosquitoes to nine (AnoACEs 1–9) and there is evidence 
that four An. gambiae genes (AnoACE2, AnoACE3, AnoACE7 and AnoACE9) are expressed in larval stages. 
AnoACE7 and AnoACE9 are predicted to have a C-terminal hydrophobic sequence that can form a membrane 
anchor45. Since the majority of the peptidyl dipeptidase activity in homogenates of larvae is soluble in nature, it 
seems likely that the activity results from expression of one or both of AnoACE2 and AnoACE3. Homology mod-
els for AnoACE2 and AnoACE3 were prepared using SWISS-MODEL46–48 with the crystal structure of Drosophila 
melanogaster ACE homologue (also known as AnCE) (PDB code 2 × 8Y)) used as the template (Fig. 5)49.
Our extensive knowledge from high resolution structural studies on how inhibitors interact with both the 
N- and C-domains of human ACE and insect ACE25,49–58 has revealed the molecular basis of binding features of 
the inhibitors and highlights differences in the inhibitor-enzyme interaction of insect ACE compared with the 
active sites of the human enzyme. Using the AnoACE homology models and amino acid sequence alignment, it 
is possible to compare different ACE proteins to look for residue and environment differences in both AnoACE2 
and AnoACE3, which could be targeted to create specific inhibitors against these enzymes. Therefore the protein 
residues forming the binding sub-sites (S2′ , S1′ S1 and S2) for the side chains of the region of the peptide (P2′ , P1′ , 
P1 and P2) spanning the catalytic site were compared between the different ACE proteins (Table 2). This shows 
that there are some residues in all four sub-sites that are conserved between human testicular ACE (tACE), which 
corresponds to the C-domain of human somatic ACE, and the insect ACEs (AnCE, AnoACE2 and AnoACE3). 
These are residues that could be targeted to increase potency of inhibitors as they are likely to be important in 
ligand binding, but this will not enhance specificity for AnoACE2 or AnoACE3. There are some residues in tACE 
that are conserved in either one, or both of the AnoACE proteins, but not in AnCE. These residues would be 
interesting to target for developing AnCE specific inhibitors. There are also some residues which are identical 
between AnCE and one, or both of the AnoACE proteins, but not tACE. This provides information for developing 
a broader insect specific inhibitor. Of particular interest to this study, some residues are unique to either one or 
both of the AnoACE proteins, and targeting these differences are the most likely route for the development of 
AnoACE2 and AnoACE3 specific inhibitors. These variations of the sub-sites have already been shown to give rise 
to different substrate and inhibitor specificities between the different ACE homologues. For example, differences 
in the S2 sub-site between the N- and C-domains of human somatic ACE have been identified as the cause of 
certain substrate and inhibitor specificity differences. In particular the substitution of F391 in the C-domain, to 
Figure 6. Surface representation looking into the S1’ and S2’ sub-sites cavity of (a) human tACE-captopril 
complex, (b) AnCE-captopril complex, (c) AnoACE2 model and (d) AnoACE3 model. The surface is coloured 
based on atom type (nitrogen in blue, oxygen in red and carbon in beige) and captopril ligands are shown as sticks. 
Selected residues are labelled to highlight differences between proteins. The figure was generated using CCP4mg60.
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Y369 in the N-domain, has been attributed to C-domain selectivity of RXPA380 (see recent review ref. 25). Both 
AnoACE2 and AnoACE3 also have a tyrosine in this position, but in addition AnoACE2 has another potentially 
significant change in the S2 sub-site with G403 replacing E403 of tACE (Table 2). This suggests that perhaps the S2 
sub-site maybe important for creating an AnoACE2 specific inhibitor, which not only lacks the charge of the E403 
found in tACE, but also has a larger binding pocket due to significantly smaller glycine residue.
There are additional notable differences between the AnoACE homologues and human tACE in the S2′ 
sub-site, and these include changes in size, shape and charge of the side-chains involved. These differences will 
cause a variation in the size, shape and localised charge of this sub-site between the different proteins, highlighted 
by the variations shown on the inner protein surface of this void (Fig. 6). Therefore the S2′ sub-site would be of 
particular interest for AnoACE specific inhibition. Additional non-conserved amino acid substitutions are found 
in the S1 and S1′ sub-sites. Although less than observed in the S2′ sub-site, they could still result in significant 
charge changes at the binding site that will in turn influence inhibitor binding.
This level of detail makes AnoACE an attractive target for applying structure-based drug design to developing 
potent and, importantly, highly selective inhibitors which could be used as insecticides. These compounds would 
need to be presented to the larvae of Ae. aegypti and An. gambiae in a particulate form to maximise oral activity 
in these filter feeders.
Methods
Chemicals. Fosinopril was purchased from Generon Ltd., Maidenhead, Berkshire, U.K. TMOF and BPP-12b 
was purchased from Biomatik USA, LLC, Wilmington, Delaware, USA. All other ACE inhibitors were purchased 
from Sigma-Aldrich Company Ltd., Poole, Dorset, U.K. The ACE substrate Abz-Phe-Arg-Lys(Dnp)-Pro-OH 
(Abz-FRK(Dnp)-P) was from Enzo Life Sciences (UK) Ltd, Exeter, U.K.
Sub-site tACE AnCE AnoACE2 AnoACE3
S1
E143 E124 E140 Q139
V351 V335 V351 V350
S355 S339 S355 S354
K368 K352 K368 K367
F512 Y496 Y512 Y511
S516 A500 A516 A515
V518 V502 V518 V517
S2
A356 A340 A356 A355
F391 F375 Y391 Y390
E403 T387 G403 E402
H410 H394 H410 H409
R522 R506 R522 R521
S1′ 
E162 D146 D162 E161
T166 E150 T166 T165
W279 W263 W279 W278
A354 A338 A354 A353
D377 Q361 E377 D376
V380 T364 V380 T379
E384 E368 E384 E383
S2′ 
N277 N261 N277 N276
Q281 Q265 Q281 Q280
T282 Q266 T282 T281
S284 S268 D284 D283
E376 D360 R376 E375
V379 F363 F379 F378
D415 D399 D415 D414
A418 S402 S418 S417
D453 D437 T453 A452
K454 K438 K454 K453
F457 F441 F457 F456
F527 F511 Y527 Y526
Table 2.  Residues involved in forming the sub-sites close to the catalytic site for human tACE, AnCE and 
modelled AnoACE2 and AnoACE3. Completely conserved residues are highlighted in italics, residues identical to 
tACE in bold, residues identical to AnCE are in bold italics, and unconserved residues are in underlined bold font.
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Mosquito culture. Ae. aegypti (Jinjang, Kuala Lumpur strain) and An. gambiae (Kisumu, Kenya strain) 
were reared in laboratory insectaries and using standard culture methods at the Faculty of Medicine and Health 
Sciences, Universiti Sains Islam Malaysia and the Liverpool School of Tropical Medicine, respectively.
Preparation of mosquito enzyme. Larvae (15, 3rd instar) were washed in distilled water 5 times for 
10 minutes and final wash for 1 hour at room temperature before storage at − 20 °C until required. Homogenate 
was prepared using a glass homogeniser (Jencons, East Grinstead, U.K.), containing 0.5 ml of 100 mM HEPES 
buffer pH 7.5, 50 mM NaCl and 10 μ M ZnCl2, and 20 up and down strokes of the pestle. A soluble fraction was 
prepared from the homogenate using a Beckman Optima™ MAX bench-top ultracentrifuge and TLA110 rotor 
(Beckman Instruments Inc, Palo Alto, Ca, U.S.A.) operating at 55,000 g (4 °C) for 1 h. Aliquots of the homogenate 
were taken prior to centrifugation to determine the relative distribution of the peptidase activity before and after 
centrifugation.
Assay of peptidyl dipeptidase activity. Rates of hydrolysis of the quenched fluorogenic substrate 
Abz-FRK(Dnp)-P by Ae. aegypti and An. gambiae enzymes were performed at 20 °C in 96-well black plastic 
plates (Corning Life Sciences, High Wycombe, U.K.) using a FLUOstar Omega (BMG LABTECH GmbH, 
Offenburg, Germany) with λ ex at 340 nm and λ em set at 430 nm). The reaction was started by adding 1 μ l of 5 mM 
Abz-FRK(Dnp)-P in dimethyl sulfoxide) to the enzyme in 200 μ l of 100 mM HEPES buffer pH 7.5, 50 mM NaCl 
and 10 μ M ZnCl2. For studying the effect of ACE inhibitors, enzyme was pre-incubated with inhibitor for 10 min 
prior to the addition of substrate.
Larvicidal activity of ACE inhibitors on Ae. aegypti and An. gambiae larvae. Larvicidal testing was 
performed in 24-well plastic plates (Becton Dickinson Labware, NJ, USA) using 20 Ae. aegypti and An. gambiae 
larvae of each L1, L2 and L3 stage in distilled water. Inhibitors dissolved in water were added separately to each 
well containing larvae to give a final concentration of 5 mM with Brewer’s yeast as the food source. Natural mor-
tality was assessed by carrying out a parallel study with the same volume of water and number of larvae in the 
absence of ACE inhibitor. Mortality in each well was recorded after 24, 48 and 72 h of exposure.
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